Episódios
-
Today's episode will focus on the topic of using genomics to accelerate drug development.
Our host is Tõnu Esko, BC Platforms SAB Chairman and Vice Director of the Institute of Genomics University of Tartu, where he also holds a Professor of Human Genomics position. He is head of the Estonian Biobank Innovation Center and focuses on public private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard at MIT. He acts as one of the senior leaders for Estonian personalized medicine programs and serves as a scientific advisor for several companies.
Our guest today is Iris Grossman, on the leading edge of Personalized Medicine, Big Data Analytics and Biotech R&D for 20 years. She is Acting CSO of Amide and advises other biotech in her field of expertise. She has held leadership positions and or consulted for top big pharma GSK, Eli Lilly, Takeda and Teva, where she was VP Head of early stage development, startup and consultancies. She specializes in leveraging high dimensional genomic insights and E-health as engines of therapeutic discovery, development and Lifecycle Management across a wide range of modalities and therapeutic areas. Iris also serves as SAB member of BC platforms, Tipa Biobank, Eleven Therapeutics and CGRP Diagnostics. She earned her B.Sc. in Medicine at the Technion, and a PhD in Medicine, Population Genomics and Pharmacogenomics for the Technion, co-mentored with the Weitzman Institute. Next, she was a postdoc fellow in Personalized Medicine and Population Genomics at Duke University.
What is covered:
- The benefits of using big data in drug discovery
- Specific examples of how the genetics could be helpful in the drug discovery, such as the contribution of human genetics and genomics to fighting COVID
- The recommendations to stakeholders for collaborating within the industry for the sake of innovation
- How biobanks can potentially act as middlemen for this new type of collaboration
Resources:
- The Institute of Genomics, University of Tartu https://genomics.ut.ee/en
- The Estonian Biobank https://genomics.ut.ee/en
- Amide Technologies https://www.amidetech.com/
- GSK https://www.gsk.com/
- Eli Lilly https://www.lilly.com/
- Takeda https://www.takeda.com/
- Teva Pharmaceutical https://www.tevapharm.com/
- Tipa Biobank https://www.ksminnovation.com/biobank
- Eleven Therapeutics https://eleventx.com/
- CGRP Diagnostics http://cgrpdiagnostics.com/
Connect with Iris Grossman:
- https://www.linkedin.com/in/irisgrossman/
Connect with Dr. Tõnu Esko:
- https://www.linkedin.com/in/tõnu-esko-24511524/
Connect with BC Platforms:
- https://www.bcplatforms.com
- https://www.linkedin.com/company/bc-platforms/
-
Today's podcast will focus on the topic of accelerated insights from data for preventative health innovation. The podcast sheds light on industry challenges and expectations as well as innovative approaches to collaboration.
This discussion is led by Tõnu Esko, BC Platforms SAB Chairman and Vice Director of the Institute of Genomics University of Tartu, where he also holds a Professor of Human Genomics position. He is head of the Estonian Biobank Innovation Center and focuses on public private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard at MIT. He acts as one of the senior leaders for Estonian personalized medicine programs and serves as a scientific advisor for several companies.
Our speaker today is Michael Geer, the co-founder of Humanity along with Peter Ward. Humanity is a health tech startup that enables you to find your rate of aging, and do what you can do to slow your aging down. Michael Geer is a serial tech entrepreneur, having amassed over a billion users with Badoo, AnchorFree, and even more revenue over his years building meaningful consumer focused technology. He wakes up every day working on how to best enable people with superpowers.
What is Covered:
- What are the main obstacles to innovation in healthcare
- How to open the access to different data types, and leverage this knowledge in order to build a complex health guide
- The importance of democratization of data, federated access, and differential privacy in making data readily usable by other people
- What scientific insights Humanity uses to build their products
- How Humanity manages the complexity of its data model, and the feedback it provides to their customers
Resources:
- The Institute of Genomics, University of Tartu https://genomics.ut.ee/en
- The Estonian Biobank https://genomics.ut.ee/en
- Humanity https://www.humanity.health/
- OpenMind https://openmindplatform.org/
- BioAge Labs https://bioagelabs.com/
Connect with Michael Geer:
- https://www.linkedin.com/in/michaelgeer
Connect with Dr. Tõnu Esko:
- https://www.linkedin.com/in/tõnu-esko-24511524/
Connect with BC Platforms:
- https://www.bcplatforms.com
- https://www.linkedin.com/company/bc-platforms/
-
Estão a faltar episódios?
-
Today's podcast will focus on the topic of the journey to a safe and secure global data access. This podcast sheds light on industry challenges and expectations, as well as innovative approaches to collaboration.
The discussion is led by Tõnu Esko, BC Platforms Scientific Advisory Board Chairman, and Vice Director of the Institute of Genomics at the University of Tartu, where he also holds a Professor of Human Genomics position. He is the Head of Estonian Biobank Innovation Center, and focuses on public-private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard and MIT. He acts as one of the senior leaders for Estonian Personal Medicine Program, and serves as scientific advisor for several companies.
Our speakers today are Jennifer Cubino and Anni-Ahonen Bishop from BC Platforms.
Jennifer Cubino is a BC Platforms COO, Customer Success and Data Science. She has many years of experience as a clinical research industry executive, most recently at IQVIA/Quintiles. She has a diverse background, including creating and leading strategic partnerships, clinical trial operations, business strategy, precision medicine, technology development and oncology. Her focus is developing high performing and engaged teams capable of tackling rapidly changing markets. With seven years of experience as a former IRB member at Tufts Medical Center, Jennifer has a deep commitment to patient wellbeing.
Anni-Ahonen Bishop has held several positions at BC Platforms before being appointed as Pharma and Research Solutions Director. She first worked as a science expert and leader as a project manager and team leader. Miss Anni Bishop has extensive experience in science communications, software design, product development and management of both large customer projects and international cross disciplinary collaboration projects.
What is covered:
- The main challenges for pharma industry in accessing healthcare data
- The harmonization of different data silos as a way of approaching and managing the technical challenges
- How BC Platforms can provide help to different data custodians to interact with the industry and make the data more readily available
- How pharma and biobanks can collaborate in order to preserve data privacy and keep it under the legal and ethical framework
Resources:
- The Institute of Genomics, University of Tartu https://genomics.ut.ee/en
- The Estonian Biobank https://genomics.ut.ee/en
- OMOP Common Data Model https://www.ohdsi.org/data-standardization/the-common-data-model/
- General Data Protection Regulation https://gdpr-info.eu/
- The Health Insurance Portability and Accountability Act https://www.hhs.gov/hipaa/index.html
Connect with Jennifer Cubino:
- https://www.linkedin.com/in/jennifercubino/
Connect with Anni Ahonen-Bishop:
- https://www.linkedin.com/in/anniahonenbishopp/
Connect with Dr. Tõnu Esko:
- https://www.linkedin.com/in/tõnu-esko-24511524/
Connect with BC Platforms:
- https://www.bcplatforms.com
- https://www.linkedin.com/company/bc-platforms/
-
Today's episode will focus on the topic of real world data access for label expansion. We are holding an open discussion with a few key leaders on how real world data can be applied in drug development to enhance research and accelerate discoveries. This podcast sheds light on industry challenges and expectations, as well as innovative approaches to collaboration.
The discussion is led by Tõnu Esko, BC Platforms Scientific Advisory Board Chairman, and Vice Director of the Institute of Genomics at the University of Tartu, where he also holds a Professor of Human Genomics position. He is the Head of Estonian Biobank Innovation Center, and focuses on public-private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard and MIT. He acts as one of the senior leaders for Estonian Personal Medicine Program and serves as scientific advisor for several companies.
Our speaker today is Jacek Nowak, Amgen's Executive Medical Director for European Midsize Markets. Jacek has been active as a pharmaceutical industry leader for over 25 years. Prior to joining Amgen in 2003, Jacek served as Medical Director for Central Europe at Wyeth, and he also worked as a Medical Doctor at the Cardiology and Intensive Care Unit at the University Hospital of Slaskie School of Medicine in Katowice, Poland. Jacek holds a degree of Medical Doctor and earned his doctorate on research work on leptin receptor polymorphism. Jacek holds a Diploma in Pharmaceutical Medicine from the Royal College of Physicians in London. His expertise pertains to the area of organ transplantation, oncology, cardiology and metabolic disorders.
What Is Covered:- What Real World Data is and how it’s connected with drug development
- The opportunity of supplementing randomised clinical trial analysis with the application of real world data
- The complexity of working with different countries, healthcare systems, and different ways in which the data is collected, in order to use the real world data in decision making process
- Expectations towards the real world data and the key properties that big data banks and healthcare systems should keep in mind when partnering with the industry in this space
- Wearables in medicine, telemedicine, digitalization of data, and other personalised medicine trends for the future of healthcare and data research
Resources:- Amgen https://www.amgen.com/
- The Estonian Biobank https://genomics.ut.ee/en
Connect with Jacek Nowak:
- https://www.linkedin.com/in/jacek-nowak-121684/
Connect with Dr. Tõnu Esko:
- https://www.linkedin.com/in/tõnu-esko-24511524/
Connect with BC Platforms:
- https://www.bcplatforms.com
- https://www.linkedin.com/company/bc-platforms/
-
Welcome to the BC Platforms Podcast!
BC Platforms is the global leader in providing a powerful data discovery and analytics platform, as well as data science solutions for personalized health care. BC Platforms enables cross-functional collaboration with our global federated network of data partners.
This episode is an open discussion with three key leaders in the healthcare data industry.
Tõnu Esko is the Professor of Human Genomics at the University of Tartu, and the longtime leader and member of the Senior Management Board for the Estonian Biobank.
Sirpa Soini is the Director of The Finnish Institute for Health and Welfare Biobank (THL Biobank). She has been collaborating with BBMRI-ERIC, and BBMRI-ERIC.fi in Finland, and with a background as a lawyer, she has also been involved in legal and ethical compliance work.
Outi Törnwall is Data Partnership Director at BC Platforms, driving forward and building a data partnership network that enables sharing of data and collaboration, particularly in industry driven research.
What is Covered:- Overview of the work of Estonian Biobank, THL Biobank and Data Partnership at BC Platforms
- The increase of real-world data and the challenges of creating meaningful databases across different industries and countries
- What positive results have been achieved so far within global data partnerships and networks
- How to bridge the gaps between academic research, industry needs and policy makers
- Advice for researchers and industry stakeholders for a more effective collaboration that benefits patients and the society as a whole
Links and Resources Mentioned in This Episode:- BC|RQUEST - Global Data Partner Network https://bcrquest.com/
- Estonian Biobank https://genomics.ut.ee/en
- THL Biobank https://thl.fi/en/web/thlfi-en
- Fingen Research Project https://www.finngen.fi/en
- Europe Biobank Week https://europebiobankweek.eu/
Connect with Sirpa Soini:
- https://www.linkedin.com/in/sirpasoini/
Connect with Outi Törnwall:
- https://www.linkedin.com/in/outitornwall/
Connect with Dr. Tõnu Esko:
- https://www.linkedin.com/in/tõnu-esko-24511524/
Connect with BC Platforms:
- https://www.bcplatforms.com
- https://www.linkedin.com/company/bc-platforms/
-
Welcome to the first episode of the BC Platforms podcast!
BC Platforms is the global leader in providing a powerful data discovery and analytics platform, as well as data science solutions for personalized health care. BC Platforms enables cross-functional collaboration with our global federated network of data partners.
In today’s episode we are discussing shaping a data access framework for population health. We will shed light on industry challenges and expectations, as well as innovative approaches to collaboration.
This episode is hosted by Tõnu Esko, BC Patforms SAB Chairman and Vice Director at the Institute of Genomics at the University of Tartu. He also holds a Professor of Human Genomics Position, and is the Head of the Estonian Biobank Innovation Center focusing on public-private partnerships and innovation transfer. Dr. Esko is a research scientist at the Broad Institute of Harvard and MIT. He acts as one of the senior leaders of the Estonian Personalized Medicine Program, and served as a scientific advisor for several companies.
Our guest today is Gerry Reilly, Chief Technology Officer at Health Data Research UK. Having joined HDR UK in 2018, Gerry is now a Technologist in Residence focusing on the development of HDR UK's international work and long term technology strategy. Gerry is a fellow of the British Computer Society, Chartered Engineer and Chartered IT professional. He's an academic assessor for the British Computer Society, and a member of the industrial advisory board for the School of Electronic, Engineering and Computer Science at QMUL.
What Is Covered:- The burning problems and the obstacles for data sharing in the global health data research community
- The three key areas HDR UK focuses on and the role of HDR UK Innovation Gateway
- How the health data research ecosystem currently works in the UK
- The cultural shifts needed in order to harmonise data access management across the health sector
- How the COVID pandemic has accelerated the work on data access and data quality harmonisation
- The steps towards a broad international collaboration in health data research
Links and Resources Mentioned in This Episode:- Health Data Research UK https://www.hdruk.ac.uk/
- Health Data Research Innovation Gateway https://www.healthdatagateway.org/
- UK Health Data Research Alliance https://ukhealthdata.org/
- UK Biobank https://www.ukbiobank.ac.uk/
- Genomics England https://www.genomicsengland.co.uk/
- Dublin Core Metadata Initiative https://dublincore.org/
- International COVID-19 Data Alliance https://icoda-research.org/
- The Estonian Biobank https://genomics.ut.ee/en
Connect with Gerry Reilly:
- https://www.linkedin.com/in/gerry-reilly-7290681/
Connect with Dr. Tõnu Esko:
- https://www.linkedin.com/in/tõnu-esko-24511524/
Connect with BC Platforms:
- https://www.bcplatforms.com
- https://www.linkedin.com/company/bc-platforms/
